Literature DB >> 18479213

FoxM1 inhibitors as potential anticancer drugs.

Andrei L Gartel.   

Abstract

BACKGROUND: The oncogenic transcription factor forkhead box M1 (FoxM1) is upregulated in a wide range of different carcinomas, while its expression is turned off in terminally differentiated cells. In addition, FoxM1 is involved in tumor invasion, angiogenesis and metastasis. For these reasons, FoxM1 is an appealing target for anticancer therapeutics. OBJECTIVE/
METHODS: In the quest to develop novel anticancer drugs we decided to target oncogenic transcription factor FoxM1 in tumor cells. Using a cell-based screening system we isolated the thiazole antibiotic siomycin A as inhibitor of FoxM1 transcriptional activity. In addition, we found that because of FoxM1 positive-autoregulation loop siomycin A and another thiazole antibiotic thiostrepton inhibit not only FoxM1 transcriptional activity but also its expression. However, the thiazole antibiotics did not affect the transcriptional activity of other transcription factors studied, suggesting that they may specifically target FoxM1. RESULTS/
CONCLUSION: Treatment of human cancer cell lines of different origins with thiazole antibiotics led to apoptosis and downregulation of FoxM1. Our data suggest that thiazole antibiotics that inhibit FoxM1 may be promising drugs against human neoplasia.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18479213     DOI: 10.1517/14728222.12.6.663

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  27 in total

1.  Targeting FoxM1 by thiostrepton inhibits growth and induces apoptosis of laryngeal squamous cell carcinoma.

Authors:  Lizhu Jiang; Xiaosong Wu; Peng Wang; Taoyu Wen; Chao Yu; Lei Wei; Hongyan Chen
Journal:  J Cancer Res Clin Oncol       Date:  2014-11-13       Impact factor: 4.553

2.  Negative regulation of the oncogenic transcription factor FoxM1 by thiazolidinediones and mithramycin.

Authors:  Vladimir Petrovic; Robert H Costa; Lester F Lau; Pradip Raychaudhuri; Angela L Tyner
Journal:  Cancer Biol Ther       Date:  2010-06-06       Impact factor: 4.742

3.  FoxM1 is a novel target of a natural agent in pancreatic cancer.

Authors:  Zhiwei Wang; Aamir Ahmad; Sanjeev Banerjee; Asfar Azmi; Dejuan Kong; Yiwei Li; Fazlul H Sarkar
Journal:  Pharm Res       Date:  2010-03-31       Impact factor: 4.200

4.  Natura-alpha targets forkhead box m1 and inhibits androgen-dependent and -independent prostate cancer growth and invasion.

Authors:  Yirong Li; Martin Ligr; James P McCarron; Garrett Daniels; David Zhang; Xin Zhao; Fei Ye; Jinhua Wang; Xiaomei Liu; Iman Osman; Simon K Mencher; Hebert Lepor; Long G Wang; Anna Ferrari; Peng Lee
Journal:  Clin Cancer Res       Date:  2011-05-23       Impact factor: 12.531

5.  Targeting FoxM1 effectively retards p53-null lymphoma and sarcoma.

Authors:  Zebin Wang; Yu Zheng; Hyun Jung Park; Jing Li; Janai R Carr; Yi-ju Chen; Megan M Kiefer; Dragana Kopanja; Srilata Bagchi; Angela L Tyner; Pradip Raychaudhuri
Journal:  Mol Cancer Ther       Date:  2013-02-20       Impact factor: 6.261

6.  FoxM1 influences embryo implantation and is regulated by 17 beta-estradiol and progesterone in mouse uteri and endometrium cells.

Authors:  Yunpeng Xie; Dan Cui; Ying Kong
Journal:  Int J Clin Exp Pathol       Date:  2014-09-15

7.  Down-regulation of FoxM1 by thiostrepton or small interfering RNA inhibits proliferation, transformation ability and angiogenesis, and induces apoptosis of nasopharyngeal carcinoma cells.

Authors:  Lizhu Jiang; Peng Wang; Lili Chen; Hongyan Chen
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

8.  A novel FoxM1-caveolin signaling pathway promotes pancreatic cancer invasion and metastasis.

Authors:  Chen Huang; Zhengjun Qiu; Liwei Wang; Zhihai Peng; Zhiliang Jia; Craig D Logsdon; Xiangdong Le; Daoyan Wei; Suyun Huang; Keping Xie
Journal:  Cancer Res       Date:  2011-12-22       Impact factor: 12.701

9.  Critical role and regulation of transcription factor FoxM1 in human gastric cancer angiogenesis and progression.

Authors:  Qiang Li; Nu Zhang; Zhiliang Jia; Xiangdong Le; Bingbing Dai; Daoyan Wei; Suyun Huang; Dongfeng Tan; Keping Xie
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

10.  FoxM1 is a general target for proteasome inhibitors.

Authors:  Uppoor G Bhat; Marianna Halasi; Andrei L Gartel
Journal:  PLoS One       Date:  2009-08-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.